CSIMarket


Johnson and Johnson  (NYSE: JNJ)
Other Ticker:  
 

Johnson and Johnson

JNJ's Fundamental analysis








Looking into Johnson And Johnson growth rates, revenue grew by 5.25 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 155

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Johnson And Johnson's net profit decreased by -89.65 % in III. Quarter 2024 year on year, to $2,694 millions.

More on JNJ's Growth


Johnson And Johnson
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Company is currently trading with Price to Cash flow multiple of 1475.24 in trailing twelve-month period.
Company
25.26
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.24.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.15.


More on JNJ's Valuation
 
 Total Debt (Millions $) 35,751
 Dividend TTM ($) 4.76 $
 Dividend Yield TTM (%) 3.21 %
 Revenue/Employee (TTM) $ 652,500
 Net Income/Employee (TTM) $ 109,256
 Receivable Turnover (TTM) 5.68
 Tangible Book Value (Per Share $) -5.82

Johnson And Johnson
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Company is currently trading with Price to Cash flow multiple of 1475.24 in trailing twelve-month period.
Company
25.26
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.24.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.15.

Johnson And Johnson Price to Book Ratio is at 5.3 lower than Industry Avg. of 88.62. and higher than S&P 500 Avg. of 0.01

More on JNJ's Valuation

  Market Capitalization (Millions $) 371,760
  Shares Outstanding (Millions) 2,428
  Employees 134,400
  Revenues (TTM) (Millions $) 87,696
  Net Income (TTM) (Millions $) 14,684
  Cash Flow (TTM) (Millions $) 252
  Capital Exp. (TTM) (Millions $) -4,401
  Total Debt (Millions $) 35,751
  Dividend TTM ($) 4.76 $
  Dividend Yield TTM (%) 3.21 %
  Revenue/Employee (TTM) $ 652,500
  Net Income/Employee(TTM) $ 109,256
  Receivable Turnover Ratio (TTM) 5.68
  Tangible Book Value (Per Share $) -5.82

  Market Capitalization (Millions $) 371,760
  Shares Outstanding (Millions) 2,428
  Employees 134,400
  Revenues (TTM) (Millions $) 87,696
  Net Income (TTM) (Millions $) 14,684
  Cash Flow (TTM) (Millions $) 252
  Capital Exp. (TTM) (Millions $) -4,401


    JNJ's Profitability Comparisons
Johnson And Johnson faced margin deterioration, primarily through cost pressure. Operating Margin fell in III. Quarter 2024 to 22.42 % from 27.96 % in II. Quarter.

Johnson And Johnson net profit margin of 11.99 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 97 in Healthcare sector and number 1150 in S&P 500.


Profitability by Segment
Total 11.99 %



  Ratio
   Capital Ratio (MRQ) 1.6
  Total Debt to Equity (MRQ) 0.51
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.53
  Inventory Turnover Ratio (TTM) 2



Johnson And Johnson faced margin deterioration, primarily through cost pressure. Operating Margin fell in III. Quarter 2024 to 22.42 % from 27.96 % in II. Quarter.

Johnson And Johnson net profit margin of 11.99 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 97 in Healthcare sector and number 1150 in S&P 500.

More on JNJ's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com